An important mechanism underlying this combination is the modulation of the tumor microenvironment by HSP90 inhibitors, as demonstrated by reduced PD-L1 expression on tumor cell surfaces and the suppression of regulatory T cell (Treg) activity and function [22,50,127]. The gene discussed is HSP90AB1; the disease is neoplasm.